“Longitudinal Analysis of Retinal Hemangioblastomatosis and Visual Function in Ocular Von Hippel-Lindau Disease”, Opthalmology, vol. 119, pp. 2622-2630, 2012.
, “Longitudinal Analysis of Retinal Hemangioblastomatosis and Visual Function in Ocular von Hippel Lindau Disease”, in Association for Research in Vision and Ophthalmology - ARVO, Ft. Lauderdale, FL, 2011.
, “Longitudinal analysis of retinal hemangioblastomatosis and visual function in ocular von Hippel-Lindau disease.”, Ophthalmology, vol. 119, no. 12, pp. 2622-30, 2012.
, “Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind”, Am Heart J, vol. 161, no. 3, pp. 487-93, 2011.
, “Rationale and Design of the Transendocardial Injection of Autologous Human Cells (Bone Marrow or Mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) Trial [..]”, Am Heart J, vol. 161, pp. 487-493, 2011.
, “Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.”, J Infect Dis, vol. 193, no. 9, pp. 1223-8, 2006.
, “Safety and Immunogenicity of a Recombinant Hemagglutinin Vaccine for H5 Influenza in Humans”, Vaccine, vol. 19, pp. 1732-1737, 2001.
, “Dose-Related Safety and Immunogenicity of A Trivalent Baculovirus-Expressed Influenza-Virus Hemagglutinin Vaccine in Elderly Adults”, J Infec Dis, vol. 193, pp. 1223-1228, 2006.
, “Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults.”, Vaccine, vol. 20, no. 7-8, pp. 1099-105, 2002.
, “A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults.”, J Infect Dis, vol. 210, no. 11, pp. 1763-71, 2014.
, “Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.”, N Engl J Med, vol. 354, no. 13, pp. 1343-51, 2006.
, “Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine”, N Engl J Med, vol. 354, pp. 1343-1351, 2006.
, “A Novel Intramuscular Bivalent Norovirus Virus-Like Particle Vaccine Candidate-Reactogenicity, Safety, and Immunogenicity in a Phase 1 Trial in Healthy Adults”, J Infect Dis, vol. pii: jiu33, 2014.
, “Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.”, Vaccine, vol. 19, no. 13-14, pp. 1732-7, 2001.
, “Evaluation of a Single Dose of Half Strength Inactivated Influenza Vaccine in Healthy Adults”, Vaccine, vol. 20, pp. 1099-1105, 2002.
, “Detection of prostate cancer and predicting progression: current and future diagnostic markers.”, Clin Cancer Res, vol. 10, no. 12 Pt 1, pp. 3943-53, 2004.
, “Detection of prostate cancer and predicting progression: current and future diagnostic markers”, Clinical Cancer Research, vol. 10, pp. 3943-3953, 2004.
, “Clinical Trials Referral Resource. Current Treatment Trials for Epithelial Ovarian Cancer”, Oncology (Williston Park), vol. 19, pp. 897-898, 900, 905-906 passim, 2005.
, “Clinical trials referral resource. Clinical trials in ovarian cancer, Part 2.”, Oncology (Williston Park), vol. 16, no. 12, pp. 1660-2, 1665-7, 2002.
, “Clinical trials referral resource. Current clinical trials investigating cancer in the elderly.”, Oncology (Williston Park), vol. 17, no. 12, pp. 1712-3, 1718-9, 2003.
, “Clinical trials referral resource. Current clinical trials in cervical cancer.”, Oncology (Williston Park), vol. 14, no. 7, pp. 1045-6, 1049-50, 2000.
, “Clinical trials referral resource. Clinical trials in ovarian cancer; Part 1.”, Oncology (Williston Park), vol. 16, no. 11, pp. 1498-9, 1504, 1506-7, 2002.
, “Clinical trials referral resource. Health-related quality of life in cancer clinical trials.”, Oncology (Williston Park), vol. 15, no. 5, pp. 601-3, 606-8, 611, 2001.
, “Clinical trials referral resource. Current clinical trials in endometrial cancer.”, Oncology (Williston Park), vol. 14, no. 6, p. 850, 855, 859, 2000.
, “Clinical trials referral resource. Current clinical trails in endometrial cancer.”, Oncology (Williston Park), vol. 17, no. 2, pp. 238-40, 244, 249, 2003.
,